Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma

Marie C Bene, PharmD,DPhil, Nelly Robillard, PhD, Philippe Moreau, MD, Soraya Wuilleme, PharmD, PhD

Blood (2019) 134 (Supplement_1): 1799.

https://doi.org/10.1182/blood-2019-130607

Published: 2019

Journal Articles

Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation

Yannick LE Bris, PharmD, Thierry Guillaume, MD PhD, Camille Debord, PharmD, Pierre Peterlin, Soraya Wuilleme, PharmD, PhD, Céline Bressollette, MD PhD, Amandine Le Bourgeois, MD, Alice Garnier, MD, Aurélie Fantou, PharmD, Marie Audrain, MD PhD, Audrey Ménard, Nelly Robillard, PhD, Marion Eveillard, Steven Le Gouill, Berthe Marie Imbert, PharmD, PhD, Marie C Bene, PharmSciD, PhD, Patrice Chevallier, MD

Blood (2019) 134 (Supplement_1): 3319.

https://doi.org/10.1182/blood-2019-122093

Published: 2019

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Blood (2016) 128 (22): 4018.

https://doi.org/10.1182/blood.V128.22.4018.4018

Published: 2016

Journal Articles

Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Murielle Roussel, MD, Valerie Lauwers-Cances, MD, Nelly Robillard, PhD, Karim Belhadj, MD, Thierry Facon, MD PhD, Laurent Garderet, MD, Martine Escoffre, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MD PhD, Denis Caillot, Cecile Fohrer, MD, Philippe Moreau, Xavier Leleu, Herve Avet-Loiseau, MD PhD, Michel Attal

Blood (2016) 128 (22): 1142.

https://doi.org/10.1182/blood.V128.22.1142.1142

Published: 2016

Journal Articles

CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy

Marion Eveillard, PharmD, PhD, Victor Floc'h, Nelly Robillard, PhD, Camille Debord, Soraya Wuilleme, PharmD, PhD, Richard Garand, Fanny Rialland, MD, Caroline Thomas, Pierre Peterlin, MD, Thierry Guillaume, MD PhD, Philippe Moreau, Patrice Chevallier, MD PhD, Marie C Bene, PharmSciD, PhD

Blood (2016) 128 (22): 5268.

https://doi.org/10.1182/blood.V128.22.5268.5268

Published: 2016

Journal Articles

In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)

Beatrice Clemenceau, PhD, Thierry Guillaume, MD PhD, Nelly Robillard, PhD, Regine Vivien, Pierre Peterlin, MD, Alice Garnier, MD, Marie-Christine Bene, Henri Vié, PhD, Patrice Chevallier, MD PhD

Blood (2016) 128 (22): 5193.

https://doi.org/10.1182/blood.V128.22.5193.5193

Published: 2016

Journal Articles

Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Blood (2015) 126 (23): 191.

https://doi.org/10.1182/blood.V126.23.191.191

Published: 2015

Journal Articles

Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome

Yannick Le Bris, PharmD, Thierry Guillaume, MD PhD, Marina Iliaquer, PharmD, Jerome Martin, PharmD, PhD, Pierre Peterlin, MD, Audrey Menard, Marion Eveillard, PharmD, Soraya Wuilleme, PharmD, PhD, Nelly Robillard, PhD, Jacques Delaunay, MD, Mohamad Mohty, MD PhD, Alice Garnier, MD, Philippe Moreau, MD PhD, Marie C Bene, PharmSciD, PhD, Patrice Chevallier, MD PhD

Blood (2015) 126 (23): 1947.

https://doi.org/10.1182/blood.V126.23.1947.1947

Published: 2015

Journal Articles

Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22 + B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study

Patrice Chevallier, Françoise Huguet, Emmanuel Raffoux, MD, Anne Etienne, MD, Thibaut Leguay, MD, Françoise Isnard, MD, Nelly Robillard, Thierry Guillaume, MD, Jacques Delaunay, MD, Pierre Peterlin, MD, Aude Charbonnier, MD, Arnaud Pigneux, MD PhD, Claire Le Houerou, David M Goldenberg, ScD, MD, William A Wegener, MD PhD, Hervé Dombret, MD PhD

Blood (2014) 124 (21): 3710.

https://doi.org/10.1182/blood.V124.21.3710.3710

Published: 2014

Journal Articles

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2014) 124 (21): 3708.

https://doi.org/10.1182/blood.V124.21.3708.3708

Published: 2014

Journal Articles

Value of Day 21 Flow Cytometry Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia (ALL) for Early Identification of Good Responders

Marion Eveillard, Nelly Robillard, Richard Garand, MD, Fanny Rialland, MD, Nicolas Blin, MD, Marion Strullu, Caroline Thomas, MD, Chantal Fossat, Isabelle Arnoux, Marie-Christine Bene, PharmSciD, PhD, Marie Loosveld

Blood (2014) 124 (21): 5358.

https://doi.org/10.1182/blood.V124.21.5358.5358

Published: 2014

Journal Articles

CD180 Expression in B-Cell Lymphomas: A Multicenter Geil Study

Caroline Mayeur-Rousse, MD, Julien Guy, Laurent Miguet, PhD, Sabrina Bouyer, Franck Genevieve, MD PhD, Nelly Robillard, Francoise Solly, MD, Aida Maar, Marie-C Bene, Laurent Mauvieux, MD PhD

Blood (2014) 124 (21): 1628.

https://doi.org/10.1182/blood.V124.21.1628.1628

Published: 2014

Journal Articles

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

Patrice Chevallier, MD, PhD, Caroline bodet-Milin, MD, Nelly Robillard, Thomas Eugene, MD, Audrey Ménard, Claire Le Houerou, Thierry Guillaume, MD, Jacques Delaunay, MD, Martine Escoffre-Barbe, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD, Françoise kraeber-Bodere, MD

Blood (2013) 122 (21): 3910.

https://doi.org/10.1182/blood.V122.21.3910.3910

Published: 2013

Journal Articles

Relative Stability Of Plasma Cells Immunophenotype In Multiple Myeloma Over Time

Benoit Tessoulin, Steven Legouill, MD PhD, Marion Eveillard, Nelly Robillard, Soraya Wuilleme, Thomas Gastinne, MD, Cyrille Touzeau, MD, Catherine Pellat-Deceunynck, PhD, Marie C Bene, PharmSciD, PhD, Philippe Moreau, MD

Blood (2013) 122 (21): 1885.

https://doi.org/10.1182/blood.V122.21.1885.1885

Published: 2013

Journal Articles

Paired Immunophenotype Comparison Of Diagnosis and Relapse Samples In B-Lineage Acute Lymphoblastic Leukemia

Marion Eveillard, Richard Garand, MD, Nelly Robillard, Soraya Wuilleme, MD, PhD, Caroline Thomas, M.D., Marion Strullu, Fanny Rialland, M.D., Jacques Delaunay, MD, Patrice Chevallier, MD, PhD, Philippe Moreau, MD, Nicolas Blin, Marie-Christine Bene, PharmSciD, PhD

Blood (2013) 122 (21): 4954.

https://doi.org/10.1182/blood.V122.21.4954.4954

Published: 2013

Journal Articles

Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain

Blood (2013) 122 (21): 3107.

https://doi.org/10.1182/blood.V122.21.3107.3107

Published: 2013

Journal Articles

Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression

Patrice Chevallier, MD, Nelly Robillard, Marina Illiaquer, Julie Esbelin, Mohamad Mohty, MD PhD, Celine Bodin-Bressollette, Thierry Guillaume, MD, Veronique Stocco, MD, Fabienne Auffray, Sophie Derenne, Lucie Planche, Marie-christine Béné, Berthe-Marie Imbert-Marcille

Blood (2012) 120 (21): 1931.

https://doi.org/10.1182/blood.V120.21.1931.1931

Published: 2012

Journal Articles

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study

Patrice Chevallier, Nelly Robillard, Aude Charbonnier, Emmanuel Raffoux, Sebastien Maury, Sylvain Carras, Cecile Chabrot, Cecile Fohrer, Marc Bernard, Jean-Sebastien Blade, Anne Etienne, Pascaline Talmant, Jacques Delaunay, Thierry Guillaume, Mohamad Mohty, Marie-Christine Bene, Norbert Ifrah, Herve Dombret

Blood (2012) 119 (11): 2474–2477.

https://doi.org/10.1182/blood-2011-11-390781

Published: 2012

Journal Articles

Trastuzumab (Herceptin®) for Treatment of Refractory/Relapsed HER2 Positive Adult B-ALL: Results of a Phase II GRAALL Study

Patrice Chevallier, MD, Nelly Robillard, Aude Charbonnier, Emmanuel Raffoux, MD, PhD, Sébastien Maury, Sylvain Carras, Cecile Chabrot, Cecile Fohrer, Marc Bernard, Jean-Sebastien Blade, Anne Etienne, MD, Pascaline Talmant, Jacques Delaunay, Thierry Guillaume, Mohamad Mohty, Norbert Ifrah, Herve Dombret

Blood (2011) 118 (21): 1525.

https://doi.org/10.1182/blood.V118.21.1525.1525

Published: 2011

NARROW

Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma

Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy

In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)

Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome

Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22 + B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Value of Day 21 Flow Cytometry Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia (ALL) for Early Identification of Good Responders

CD180 Expression in B-Cell Lymphomas: A Multicenter Geil Study

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

Relative Stability Of Plasma Cells Immunophenotype In Multiple Myeloma Over Time

Paired Immunophenotype Comparison Of Diagnosis and Relapse Samples In B-Lineage Acute Lymphoblastic Leukemia

Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain

Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study

Trastuzumab (Herceptin®) for Treatment of Refractory/Relapsed HER2 Positive Adult B-ALL: Results of a Phase II GRAALL Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only